focus -WSS

focus

author：hotspot 2025-08-04 03:41:56 - browse：2

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Covid isolation guidance eased by the CDC

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Stop Congress from blocking public access to science

Study points to new risk in gene therapy death of Terry Horgan

Congress extends some pandemic preparedness programs

WHO recommends second malaria vaccine

2023 Nobel Prize in Medicine goes to Karikó and Weissman

focus

focus

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

New oral drug delivery patch is modeled after octopus tentacles

Dobbs anniversary: the lost opportunity of abortion as health care

Health insurers' Q3 question: how much care are people getting?

Hollywood unions extend contract negotiations for actors

International team creates first chimeric human

Duchenne breakthrough therapy leaves behind pioneering families

New oral drug delivery patch is modeled after octopus tentacles

In age of alternative facts, a scholarly course on calling out crap

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

explore

Kenai launches with $82 million for Parkinson’s stem cell therapy

How to address the problem of discarded donor organs

Change Healthcare cyberattack outage could last weeks

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Biotech companies concerned about China biosecurity crackdown

IVG is promising — but it won’t replace IVF quite yet

explore

focus

explore

leisure time